dr. barbara j. gitlitz on why pd-l1 is not a good biomarker for immunotherapy in lung cancer
Published 7 years ago • 329 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:24
dr. lilenbaum on pd-l1 as a predictive biomarker for immunotherapy in lung cancer
-
1:21
dr. kim discusses pd-l1 as a biomarker in lung cancer
-
2:24
dr. weiss on pd-l1 biomarker in lung cancer
-
1:00
dr. gitlitz discusses the genomics of young lung cancer study
-
5:06
should pd-l1 be used as a biomarker for immunotherapy in lung cancer?
-
10:20
pd-l1 testing in advanced lung cancer
-
1:42
dr. gandara discusses pd-l1 as a biomarker in lung cancer
-
1:41
dr. goldberg on pd-l1 as a biomarker in lung cancer
-
7:34
pd-l1 as a biomarker in squamous non-small cell lung cancer
-
1:34
evolving role of pd-l1 as a biomarker
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
1:12
dr. sharma on pd-l1 as biomarker for immunotherapy in bladder cancer
-
3:19
frontline pd-l1 monotherapy: keynote-042 and impower110
-
1:03
dr. costa on biomarkers beyond pd-l1 for immunotherapy in nsclc
-
5:36
first-line therapy in pd-l1–advanced nsclc
-
4:47
pd-l1 biomarker testing
-
1:33
dr. anne chiang on molecular testing in lung cancer treatment planning
-
4:50
nsclc: challenges with pd-l1 as biomarker
-
7:42
therapy approach for pd-l1 over 50% lung cancer